Open label, multiple dose, sequential, drug-drug interaction study to assess the pharmacokinetics and safety of atazanavir and raltegravir co-administered twice daily in healthy subjects

Trial Profile

Open label, multiple dose, sequential, drug-drug interaction study to assess the pharmacokinetics and safety of atazanavir and raltegravir co-administered twice daily in healthy subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Nov 2008

At a glance

  • Drugs Atazanavir; Raltegravir
  • Indications HIV-1 infections
  • Focus Adverse reactions
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 05 Nov 2008 Actual patient number (22) added as reported by ClinicalTrials.gov.
    • 10 Sep 2007 Status changed from initiated to recruiting.
    • 28 Aug 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top